About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2013 (2013), Article ID 168012, 8 pages
http://dx.doi.org/10.1155/2013/168012
Research Article

Incidence, Mortality, and Predictive Factors of Hepatocellular Carcinoma in Primary Biliary Cirrhosis

1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
2Department of Pathology, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan

Received 1 December 2012; Accepted 18 January 2013

Academic Editor: Bjørn Moum

Copyright © 2013 Kenichi Hosonuma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Howel, J. V. Metcalf, J. Gray, et al., “Cancer risk in Primary biliary cirrhosis: a study in northern England,” Gut, vol. 45, no. 5, pp. 756–760, 1999. View at Google Scholar
  2. A. Floreani, A. Baragiotta, V. Baldo, et al., “Hepatic and extrahepatic malignancies in Primary biliary cirrhosis,” Hepatology, vol. 29, no. 5, pp. 1425–1428, 1999. View at Google Scholar
  3. D. E. Jones, J. V. Metcalf, J. D. Collier, et al., “Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes,” Hepatology, vol. 26, no. 5, pp. 1138–1142, 1997. View at Google Scholar
  4. A. Shibuya, K. Tanaka, H. Miyakawa, et al., “Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis,” Hepatology, vol. 35, no. 5, pp. 1172–1178, 2002. View at Google Scholar
  5. W. M. Melia, P. J. Johnson, J. Neuberger, S. Zaman, B. C. Portmann, and R. Williams, “Hepatocellular carcinoma in primary biliary cirrhosis: detection by α-fetoprotein estimation,” Gastroenterology, vol. 87, no. 3, pp. 660–663, 1984. View at Google Scholar · View at Scopus
  6. Y. Nakanuma, T. Terada, K. Doishita, and A. Miwa, “Hepatocellulr carcinoma in primary biliary cirrhosis: an autopsy study,” Hepatology, vol. 11, no. 6, pp. 1010–1016, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Krasner, P. J. Johnson, B. Portmann, et al., “Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases,” Gut, vol. 20, no. 3, pp. 255–258, 1979. View at Google Scholar
  8. H. T. Sorensen, S. Frijs, J. H. Olsen, et al., “Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark,” Hepatology, vol. 28, no. 4, pp. 921–925, 1998. View at Google Scholar
  9. P. K. Nijhawan, T. M. Therneau, E. R. Dickson, et al., “Incidence of cancer in Primary biliary cirrhosis: the Mayo experience,” Hepatology, vol. 29, no. 5, pp. 1396–1398, 1999. View at Google Scholar
  10. L. Loof, H. O. Adami, P. Sparen et al., “Cancer risk in Primary biliary cirrhosis: a population-based study from Sweden,” Hepatology, vol. 20, no. 1, pp. 101–104, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Cavazza, L. Caballerí, A. Floreani et al., “Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers,” Hepatology, vol. 50, no. 4, pp. 1162–1168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Scheuer and J. Lefkowitch, Liver Biopsy Interpretation, WB Saunders, London, UK, 1994.
  13. M. I. Prince, A. Chetwynd, W. L. Craig, et al., “Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort,” Gut, vol. 53, no. 6, pp. 865–870, 2004. View at Google Scholar
  14. R. E. Poupon, B. Balkau, E. Eschwege, and R. Poupon, “A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis,” The New England Journal of Medicine, vol. 324, no. 22, pp. 1548–1554, 1991. View at Google Scholar · View at Scopus
  15. P. Angulo, K. P. Batts, T. M. Therneau, R. A. Jorgensen, E. R. Dickson, and K. D. Lindor, “Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis,” Hepatology, vol. 29, no. 3, pp. 644–647, 1999. View at Google Scholar · View at Scopus
  16. K. D. Lindor, R. A. Jorgensen, T. M. Therneau, M. Malinchoc, and E. R. Dickson, “Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis,” Mayo Clinic Proceedings, vol. 72, no. 12, pp. 1137–1140, 1997. View at Google Scholar · View at Scopus
  17. R. E. Poupon, K. D. Lindor, K. Cauch-Dudek, E. R. Dickson, R. Poupon, and E. J. Heathcote, “Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis,” Gastroenterology, vol. 113, no. 3, pp. 884–890, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Corpechot, O. Chazouillères, and R. Poupon, “Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome,” Journal of Hepatology, vol. 55, no. 6, pp. 1361–1367, 2011. View at Google Scholar
  19. Y. Takeuchi, F. Ikeda, S. Fujioka, et al., “Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid,” Journal of Gastroenterology and Hepatology, vol. 26, no. 9, pp. 1395–1401, 2011. View at Google Scholar
  20. R. Hazzan and R. Tur-Kaspa, “Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid,” Journal of Clinical Gastroenterology, vol. 44, no. 5, pp. 371–373, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Iwasaki, H. Ohira, S. Nishiguchi et al., “The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study,” Hepatology Research, vol. 38, no. 6, pp. 557–564, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Nakamuta, M. Enjoji, K. Kotoh, N. Shimohashi, and Y. Tanabe, “Long-term fibrate treatment for PBC,” Journal of Gastroenterology, vol. 40, no. 5, pp. 546–547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Angulo, K. D. Lindor, T. M. Therneau et al., “Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid,” Liver, vol. 19, no. 2, pp. 115–121, 1999. View at Google Scholar · View at Scopus
  24. A. Pares, L. Caballeria, and J. Rodes, “Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid,” Gastroenterology, vol. 130, no. 3, pp. 715–720, 2006. View at Google Scholar
  25. C. Corpechot, L. Abenavoli, N. Rabahi et al., “Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis,” Hepatology, vol. 48, no. 3, pp. 871–877, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. M. Kuiper, B. E. Hansen, R. A. de Vries, et al., “Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid,” Gastroenterology, vol. 136, no. 4, pp. 1281–1287, 2009. View at Google Scholar
  27. T. Kumagi, M. Guindi, S. E. Fischer et al., “Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis,” American Journal of Gastroenterology, vol. 105, no. 10, pp. 2186–2194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Nakano, K. Inoue, J. Hirohara et al., “Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC),” Hepatology Research, vol. 22, no. 4, pp. 250–260, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. U. Leuschner, “Primary biliary cirrhosis-presentation and diagnosis,” Clinical Liver Disease, vol. 7, no. 4, pp. 741–758, 2003. View at Google Scholar
  30. Y. Muto, S. Sato, A. Watanabe, et al., “Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 3, no. 7, pp. 705–713, 2005. View at Google Scholar
  31. Y. Muto, S. Sato, A. Watanabe et al., “Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis,” Hepatology Research, vol. 35, no. 3, pp. 204–214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Kobayashi, K. Ikeda, Y. Arase, et al., “Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus,” Journal of Gastroenterology, vol. 43, no. 1, pp. 63–70, 2008. View at Google Scholar
  33. H. Fukushima, Y. Miwa, M. Shiraki, et al., “Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis,” Hepatology Research, vol. 37, no. 9, pp. 765–770, 2007. View at Google Scholar
  34. Y. Inoue, A. Koizumi, Y. Wada, et al., “Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study,” Journal of Epidemiology, vol. 17, no. 6, pp. 194–202, 2007. View at Google Scholar
  35. G. M. Van Dam and C. H. Gips, “Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures,” Scandinavian Journal of Gastroenterology, vol. 32, no. 1, pp. 77–83, 1997. View at Google Scholar · View at Scopus